TWI308148B - Novel compound of 6-methyl-3-phenethyl-3,4-dihydro-1h-quinazoline-2-thione, its preparation and a depigmentation composition containing the same as an effective component - Google Patents
Novel compound of 6-methyl-3-phenethyl-3,4-dihydro-1h-quinazoline-2-thione, its preparation and a depigmentation composition containing the same as an effective component Download PDFInfo
- Publication number
- TWI308148B TWI308148B TW092133158A TW92133158A TWI308148B TW I308148 B TWI308148 B TW I308148B TW 092133158 A TW092133158 A TW 092133158A TW 92133158 A TW92133158 A TW 92133158A TW I308148 B TWI308148 B TW I308148B
- Authority
- TW
- Taiwan
- Prior art keywords
- methyl
- dihydro
- melanin
- thione
- phenylethyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title description 26
- 150000001875 compounds Chemical class 0.000 title description 12
- 238000002360 preparation method Methods 0.000 title description 5
- LBIVXNVXHYOGIM-UHFFFAOYSA-N 6-methyl-3-(2-phenylethyl)-1,4-dihydroquinazoline-2-thione Chemical compound C1C2=CC(C)=CC=C2NC(=S)N1CCC1=CC=CC=C1 LBIVXNVXHYOGIM-UHFFFAOYSA-N 0.000 title 1
- 230000035614 depigmentation Effects 0.000 title 1
- -1 quinazoline 2 - thione compound Chemical class 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 8
- 239000002689 soil Substances 0.000 claims description 5
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 2
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 claims description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229940117803 phenethylamine Drugs 0.000 claims description 2
- 101100074846 Caenorhabditis elegans lin-2 gene Proteins 0.000 claims 1
- 101100497386 Mus musculus Cask gene Proteins 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 74
- 210000004027 cell Anatomy 0.000 description 43
- 230000002087 whitening effect Effects 0.000 description 27
- 201000001441 melanoma Diseases 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 229940088597 hormone Drugs 0.000 description 13
- 239000005556 hormone Substances 0.000 description 13
- 230000008099 melanin synthesis Effects 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000002537 cosmetic Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 12
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 12
- 229960004705 kojic acid Drugs 0.000 description 12
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 102000003425 Tyrosinase Human genes 0.000 description 10
- 108060008724 Tyrosinase Proteins 0.000 description 10
- 210000002752 melanocyte Anatomy 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 208000000069 hyperpigmentation Diseases 0.000 description 8
- 230000003810 hyperpigmentation Effects 0.000 description 8
- 239000000049 pigment Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229960000271 arbutin Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 206010014970 Ephelides Diseases 0.000 description 5
- 208000003351 Melanosis Diseases 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 238000004042 decolorization Methods 0.000 description 5
- 238000002845 discoloration Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019833 protease Nutrition 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 4
- YPXQSGWOGQPLQO-UHFFFAOYSA-N 5-nitro-1,3-dihydrobenzimidazole-2-thione Chemical class [O-][N+](=O)C1=CC=C2N=C(S)NC2=C1 YPXQSGWOGQPLQO-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- QPCIUXWQCCFLCI-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl acetate Chemical compound CC(=O)OC(CO)CO QPCIUXWQCCFLCI-UHFFFAOYSA-N 0.000 description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 3
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101001091368 Rattus norvegicus Glandular kallikrein-7, submandibular/renal Proteins 0.000 description 3
- 101000898773 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Saccharopepsin Proteins 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 244000003892 Vaccinium erythrocarpum Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 108010056599 proteinase C Proteins 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 235000008160 pyridoxine Nutrition 0.000 description 3
- 239000011677 pyridoxine Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 description 2
- JUZVVVRKVMKYBU-UHFFFAOYSA-N 4-methyl-2-[(2-phenylethylamino)methyl]aniline Chemical compound CC1=CC=C(N)C(CNCCC=2C=CC=CC=2)=C1 JUZVVVRKVMKYBU-UHFFFAOYSA-N 0.000 description 2
- ZPTVNYMJQHSSEA-UHFFFAOYSA-N 4-nitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C=C1 ZPTVNYMJQHSSEA-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- OURRXQUGYQRVML-AREMUKBSSA-N [4-[(2s)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate Chemical compound CC1=CC(C)=CC=C1C(=O)OCC1=CC=C([C@@H](CN)C(=O)NC=2C=C3C=CN=CC3=CC=2)C=C1 OURRXQUGYQRVML-AREMUKBSSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 108010051081 dopachrome isomerase Proteins 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- RABZYUWMIDILPP-UHFFFAOYSA-N 1,3-bis(sulfanyl)propane-1,2,3-triol Chemical compound SC(C(C(O)S)O)O RABZYUWMIDILPP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- VHLKLAIAIMYSAM-UHFFFAOYSA-N 2-(ethoxymethyl)-N-methylaniline Chemical compound CCOCC1=CC=CC=C1NC VHLKLAIAIMYSAM-UHFFFAOYSA-N 0.000 description 1
- MOMFXATYAINJML-UHFFFAOYSA-N 2-Acetylthiazole Chemical group CC(=O)C1=NC=CS1 MOMFXATYAINJML-UHFFFAOYSA-N 0.000 description 1
- IXGJKTBMOREOLH-UHFFFAOYSA-N 2-phenylethanamine;phenylmethanamine Chemical compound NCC1=CC=CC=C1.NCCC1=CC=CC=C1 IXGJKTBMOREOLH-UHFFFAOYSA-N 0.000 description 1
- WHNCXIBKVUPNHR-UHFFFAOYSA-N 3,4-dihydroxy-1h-indole-2-carboxylic acid Chemical compound C1=CC(O)=C2C(O)=C(C(=O)O)NC2=C1 WHNCXIBKVUPNHR-UHFFFAOYSA-N 0.000 description 1
- SGNZYJXNUURYCH-UHFFFAOYSA-N 5,6-dihydroxyindole Chemical compound C1=C(O)C(O)=CC2=C1NC=C2 SGNZYJXNUURYCH-UHFFFAOYSA-N 0.000 description 1
- YFTGOBNOJKXZJC-UHFFFAOYSA-N 5,6-dihydroxyindole-2-carboxylic acid Chemical compound OC1=C(O)C=C2NC(C(=O)O)=CC2=C1 YFTGOBNOJKXZJC-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- GIQKIFWTIQDQMM-UHFFFAOYSA-N 5h-1,3-oxazole-2-thione Chemical compound S=C1OCC=N1 GIQKIFWTIQDQMM-UHFFFAOYSA-N 0.000 description 1
- SBZBDWBZQAABFX-UHFFFAOYSA-N 7-(2-amino-2-carboxyethyl)-2-[7-(2-amino-2-carboxyethyl)-5-oxo-1,4-benzothiazin-2-yl]-5-hydroxy-4H-1,4-benzothiazine-3-carboxylic acid Chemical compound NC(Cc1cc(O)c2NC(C(O)=O)=C(Sc2c1)c1cnc2c(cc(CC(N)C(O)=O)cc2=O)s1)C(O)=O SBZBDWBZQAABFX-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- 230000002176 calcinogenic effect Effects 0.000 description 1
- WHPULOBNBOSLJB-UHFFFAOYSA-N carbazole-2-thione Chemical compound S=C1C=C2N=C3C=CC=CC3=C2C=C1 WHPULOBNBOSLJB-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- QECQLMGRLZYSEW-UHFFFAOYSA-N decoxybenzene Chemical compound CCCCCCCCCCOC1=CC=CC=C1 QECQLMGRLZYSEW-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 230000008101 melanin synthesis pathway Effects 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- AALKGALVYCZETF-UHFFFAOYSA-N pentane-1,2,3-triol Chemical compound CCC(O)C(O)CO AALKGALVYCZETF-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 1
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
1308148 玖、發明說明: 【發明所屬之技術領域】 本發明係關於一種結構式1所示之新穎之6-甲基-3-苯乙基 -3,4-二氫林-2-硫酮化合物;其製造方法;一種包含以前 述化合物作為有效成分之用於預防及治療色素過度沈著症的醫 藥組合物;及一種包含以前述化合物作為有效成分之皮膚美白化 妝品組合物。
【先前技術】 皮膚會變黑及暗沉的原因,是由於黑色素細胞在紫外線照 射、賀爾蒙不平衡或心理壓力等情況下合成了過多的黑色素(一種 天然色素)(Nordlund,J. J. et al.,The Pigmentation System: Physiology and Pathophysiology. New York, Oxford Univ. Press, pp. 1-1025, 1998)。因此,控制黑色素合成的技術成為發產美白產 品的核心技術,美白產品是用來預防皮膚中產生過量的黑色素或 淡化已累積於皮膚中的黑色素以抑制色素過度沈著症如脫色或 雀斑。(Hori,W.,Drug Discovery Approaches for Developing Cosmeceuticals. Advanced Skin Care and Cosmetic Products. Southborough, IBC Library Series, pp. 3.1.1-3.1.21, 1997) ° 按照黑色素生物合成程序,起始材料酪胺酸(tyrosine)由酪胺 酸酵素轉變為多巴(DOPA)及多巴醌(DOPAquinone);多巴在5,6- 1308148 二羥吲哚2-羧酸及5,6-二羥吲哚的參與下產生兩種真黑色素 (eumelanins);多巴酿與半胱氨酸(cysteine)反應產生苯黑色素。從 5,6-二羥吲哚2-羧酸衍生出的真黑色素是一種棕色色素,從5,6-二羥"5丨哚衍生的真黑色素是一種黑色色素及嗜鉻黑色素是一種黃 -紅色色素。(Hearing, V. J.,FASEB J·, 5:2902-9, 1991; Hearing,V. J·,J. Invest· Dermatol.,4:24-8,1999)。 根據基因剔除研究,缺乏酪胺酸酵素會造成白子(白老鼠), 而缺乏酪胺酸酵素相關蛋白質2(TRP-2)則會造成灰子。並且,目 前已知酪胺酸酵素相關蛋白質l(TRP-l)在棕色發展中扮演重要的 角色(Rieder, S.,et al·,Mamm· Genome, 12:450-5,2001; Tanita, M., et al., J. Hum. Genet., 47:1-6, 2002; Kameyama, K., et al., Pigment Cell Res·, 8:97-104,1995)。酪胺酸酵素相關蛋白質1在 人體内沒有表現出任何酵素活性,但其在老鼠體内則表現出5,6-二氫61# 2-羧酸氧化酵素的酵素活性,並且已知與穩定酪胺酸酵 素有關(Kobayashi,T.,et al.,J. Biol. Chem.,272:31801-5, 1998)。 紫外線在皮膚的黑色素合成中扮演著重要角色。當黑色素細 胞暴露於紫外線下時,其能藉由二醯基甘油活化蛋白質酵素C, 進而促進黑色素的合成(Gilchrest,B. A.,et al., Photochem. Photobiol., 93:1-10, 1996; Park, Η. Y., et al., J. Biol. Chem., 274:16470-8,1999)。暴露於陽光下時,角質細胞釋放出一氧化 氮,α -黑色素細胞刺激贺爾蒙前列腺素E2及内皮素-1。這些釋 放因子會轉移給黑色素細胞,其中一氧化氮經由cGMP訊息傳遞 及蛋白質酵素G增加黑色素的合成,而停止釋放這些因子則會經 由cAMP的訊息傳遞及蛋白質酵素A增加黑色素的合成 (Romero-Graillet, C., et al., J. Biol. Chem., 271:28052-6, 1996; Rasmussen, N., et al., Neuroendocrinol. Lett., 20:265-282, 1999;
Scott, M. C., et al.,J. Cell. Sci. 115:2349-55, 2002)。 1308148 在發展抑制色素過度沉著症的皮膚美白產品中,了解黑色素 合成路徑非常重要(discloration,freckles, etc·)。代表性的例子為 黑色素生物合成抑制劑’發展到目前為止包含曲酸(k〇jic add)、 熊果素(arbutin)、維他命C、桑椹萃取物、甘草萃取物及其他相 似的成分。曲酸與一銅離子螯合需要酪胺酸酵素的活化,其能抑 制黑色素的合成,具有優越的美白功效。然而,近來曲酸被認為 是一種鈣生成試劑(calcinogenic agent),因而限制了曲酸的用途。 維他命C及其衍生物表現出相對較低的美白功效。氫醌則由於對 皮膚具有尚刺激性,基於安全考量而限制其應用範圍。此外,目 别已知植物卒取物只有在高濃度下才能表現出脫色效果,幾乎沒 有任何植物萃取物能在低濃度下表現出脫色能力。 因此,為了解決傳統黑色素合成抑制劑的問題,並尋求一種更 佳的美白物質,本發明之發明人藉由多次極化活性分析處理篩選 後,發現一新穎之6_甲基_3_苯乙基_3,4·二氫_17^奎唑琳_2_硫酮化 合物。並且,我們確定以該化合物作為有效成分之醫藥組合物及 化妝品組合物具有良好的皮膚美白功效,並根據該項發現完成本 發明》 本發明提供一新穎之6-甲基-3-苯乙基_3,4_二氫喳唑啉 2石瓜酮化合物及其製造方法,及包含以前述化合物作為有效成分 之用於預防及治療色素過度沈著症的醫藥組合物及皮膚美白化 妝品組合物。 【發明内容】 本發明係關於一種結構式i所示之新顆t 6_甲基_3_苯乙基 -、3,4-二氫_1札喳唑啉_2_硫酮化合物;其製造方法;一種包含以前 ,化=物作為有效成分之用於預防及治療色素過度沈著症的醫 樂組合物;及—種包含以前述化合物最為有效成分之皮膚美白化 妝品組合物。 9 1308148 h3c
在本發明中,結構式1所示之6_甲基_3_苯乙基3 _ 喳唑啉-2-硫酮化合物係可藉由反應結構式4所示^ 二氫-1H- 乙基-3,4-二氫-1//+坐琳與Lawes_,s ^甲基-3-笨 程圖1所示。 表備’如流 反應流程圖 h3c
⑷
在前述之反應流程圖1中,結構式4之6-甲基-3-苯乙基_3 4 二氫-l/ί-喳唑啉-2-酮之製備係如下面反應流程圖2所示,先將龄 構式2之(5-甲基-2-硝基苯)苯乙基胺還原,獲得結構式3之4·甲 基-2-(本乙基氣甲基)苯基胺,然後將產物與1,1 ί炭基二咪唾反 應,即製備得結構4之化合物。 1308148 反應流程圖2
在前述之反應流程圖中,結構式2之(5-甲基-2-硝基苯)苯 乙基胺係可藉由反應5-甲基-2-硝基苯氣與苯乙基胺來製備,如 下列反應流程圖3所示。 反應流程圖3
製備本發明結構式1所不之6-甲基-3-苯乙基- 3,4 -二鼠-1 // 喳唑啉-2-硫酮化合物的方法係摘要於反應流程圖4中。 11 1308148 反應流程圖4
⑴ (4) 在另一方面,本發明係關於係關於一種包含6_甲基_3_苯乙 基-3,4-二氫奎唑啉_2_硫酮化合物之用於預防及治療色素過 度沈著症的醫藥組合物。該醫藥組合物較佳係包含含量為醫藥 組合物全部重量之0.0001至1%的6_甲基_3_苯乙基_34二氫 -1仏喳唑啉_2_硫酮化合物。 該醫藥組合物係用於預防及治療黑色素過度沉著症如脫 色、雀斑、高齡色素模糊及其他相似問題,並可利用不同的藥 物學上可接受之載體、賦型劑及/或添加劑配製成不同配方。代 表性的例子包含皮膚配方如乳霜、軟膏、凝膠、塗劑或貼布。 在另一方面’本發明係關於一種包含6_甲基_3_苯乙基_3,4_ 二氫奎唾啉_2-硫酮化合物之美白化妝品組合物。該美白化 妝品組合物較佳係包含含量為美白化妝品組合物全部重量之 〇.0001至1%的6-甲基-3_苯乙基-3,4-二氫-1//-喳唑啉-2-硫酮化 合物。 12 1308148 皮膚美白化妝品組合物係用來治療或預防皮膚色素異常如 脫色、雀斑、高齡色素模糊及其他相似問題,其配方並無特殊 限制。代表性的配方例子包含調色劑、收斂劑、滋養霜、按摩 霜、精華液、面膜、凝膠、化妝水、貼片、喷液或液體粉末。 本發明合成之6-甲基-3-苯乙基-3,4 -二氮-1//-奎σ坐σ林-2-硫 酮化合物可抑制黑色素經由蛋白質酵素C、cAMP/蛋白質酵素 A、或經由cGMP/蛋白質酵素G而合成,無細胞毒性,並且具 有優於本技術領域已知的曲酸及熊果苷幾百倍的美白效果。 【實施方式】 本發明係藉由下列實施例、配方實施例及實驗實施例進一 步詳細說明,然而其並非用於限制本發明。 貫施例1 .製備6-甲基-3 -苯乙基-3,4 -二氮-1 邊11坐σ林-2-硫嗣 貫施例 1-1 .合成(5 -甲基-2 _石肖基笨)苯乙基胺 將苯乙基胺(2 eq. wt·,3.38 ml)及三乙基胺(3 eq. wt.,5.6 ml) 溶解於四氳呋喃,並將溶於四氫呋喃之5-甲基-2-硝基苯氣(2.5 g,0.0135莫耳)加入前述溶液中。該混合物在室溫下攪拌10分 鐘,並在60至70°C迴流12小時。將反應冷卻至環境溫度並真 空蒸餾。有機層以無水硫酸鈉除水,真空蒸餾,並以管柱分離。 (5-曱基-2-硝基苯)苯乙基胺之特徵係如下所述。 橘色油狀物;
Rf=0_26(己烷:乙基醋酸=2 : 1);產率84.8% ; IR(KBr) 3350, 3050, 3020, 2930, 2850,1610,1585,1520, 1455, 1340, 1265, 1120cm'1; lR NMR(CDC13, 89.45MHz) δ 2.40(s, 3H), 2.88(m, 4H), 4.03(s, 2H), 7.13-7.93(m, 8H) 13 1308148 實施例1-2 :合成4-甲基-2-(笨乙基氨甲基)笨基胺 (5-甲基-2-硝基苯)苯乙基胺(3 g)溶解於二氯甲烷與甲醇 (1 : 1)之混合物中。加入碳化鈀(240 mg)於前述溶液中,該混合 物在氫壓30 psi下擾拌4小時。透過賽力特塊(celite caket)抽 濾反應物,並以二氣甲烷清洗。將濾出液真空蒸餾以獲得4-甲 基-2-(苯乙基氨甲基)苯基胺。產物之特徵係如下所述。 棕色油狀物;
Rf=0.045(己烷:乙基醋酸=2 : 1);產率89.7% ; IR(KBr) 3550-3200,3025, 2930, 2895,2750, 1620,1500, 1455, 1265cm'1; *H NMR(CDC13, 89.45MHz) δ 2.20(s, 3H), 2.83(m, 2H), 2.91(s, 2H), 3.91(m, 2H), 4.27(br, NH2), 6.41-7.21(m, 8H) 實施力1-3 :合成6-甲基-3-笨乙基-3,4-二氫唑啉-2-酮 將4-甲基-2-(苯乙基氨甲基)苯基胺(2 g,0.00832莫耳)溶解 於無水四氫α夫喃。加入1,1’ -幾基咪吐(1.1 eq. wt·,1.48 g)。使 混合物在50至60°C迴流12小時。移除四氫呋喃,以水合二氯 甲烷萃取。有機層以無水硫酸鈉除水,真空蒸餾,並以管柱分 離。6-甲基-3-苯乙基-3,4-二氫-1 //-碴唑啉-2-酮之特徵係如下所 述。 黃色固體;
Rf=〇_34(己烷:乙基醋酸=5 : 1); 產率81.9% ;熔點 174.8-175.8°C ; IR(KBr) 3200,3100-3000, 2920,1650,1610, 1500,1455, 1320, 1270, 1240, 1180cm'1; lU NMR(CDC13, 89.45MHz) δ 2.25(s, 3H), 2.95(t, J=7.5 , 14 1308148 2H), 3.67(t, J=7.5 , 2H), 4.31(s, 2H), 6.57-7.01(m, 3H), 7.26(m, 5H), 7.88(br, NH) 實施例 1-4:合成6-甲基-3-笨乙基-3,4-二氫-1//-喹唑啉-2-硫酮 6-甲基-3-苯乙基-3,4-二氫-1//-喳唑啉-2-酮(880 mg,0.0033 莫耳)溶解於甲苯並加熱。加入Lawesson's反應試劑(0.6 eq. wt.,802 mg)。混合物在100°C迴流8小時。藉由真空蒸餾移除 甲苯,然後以水合二氣甲烷萃取。有機層以無水硫酸鈉除水, 真空蒸餾,並以管柱分離。6-甲基-3-苯乙基-3,4-二氫-1//-喳唑 φ 啉-2-硫酮之特徵係如下所述。 淡黃色固體;Rf=〇.63(己烷:乙基醋酸=2 : 1); 產率 47.2% ;熔點 177.2-177.7°C ; IR(KBr) 3200, 3020, 2920, 1620, 1550-1480, 1450, 1325, 1265, 1240, 1 175, 1150cm·1 ; !H NMR(CDC13, 89.45MHz) δ 2.27(s, 3H), 3.10(t, J=7.7 , 2H), 4.12(t, J=7.7 , 2H), 4.36(s, 2H), 6.60-7.02(m, 3H), 7.28(m, 5H), 8.48(br, NH);
Anal. Calcd. for C17H18N2S C,72.3; H,6.42; N;9.92; S,11.3 _
Found: C,71.9; H,6.89; N,8.64; S,13.1 15 1308148 組成物配方 配方1.包含6-甲基-3-苯乙基-3,4-二氫-1丑-喹唑啉-2-硫酮化合物 之用於預防及治療色素過度沈著症的醫藥組合物—藥膏 成分 含量 6-甲基-3-苯乙基-3,4-二氫 -1 η奎唾琳-2 -硫酮 〇.5g 白堪 4.0 g 膽固醇 1.6 g 白色凡士林 剩餘部分 十六烷醇 1.6 g 總計 100 g 配方2.包含6-甲基-3-苯乙基-3,4-二氮-1_ΒΓ-β奎峻琳-2-硫明化合物 之用於預防及治療色素過度沈著症的醫藥組合物_凝膠 成分 含量 6-曱基-3-苯乙基-3,4-二氫 奎哇琳-2-硫酮 〇.5g 乙醇 18 g 高嶺土 5 g 1,3-丁二醇 5 g 甘油 8g CMC-鈉 9g 明膠 3 g 甲基酉旨(methylparabene) 0.1 g 丙基醋(propylparabene) 0.2 g 16 1308148 純水 其他部分 總計 100 g 配方3.包含6-甲基-3-苯乙基-3,4·二氫-1丑-喳唑啉-2-硫酮化合 物之美白化妝品組合物-滋養霜 成分 含量 三乙醇胺 0.1 g 甘油 3.0 g 丁浠乙二醇 3.0 g 液態石堪 7.0 g yS-葡萄聚糖 7.0 g 卡波姆(Carbomer) 0.1 g 6-甲基-3-苯乙基-3,4-二氫 〇.5g -1开-σ奎σ全u林-2 ·硫酉同 辛酸/癸酸三甘油脂 3.0 g 鯊烯 5.0 g 十六硬醋酸葡萄糖昝 1.5 g 硬脂酸山梨糖醇酯 0.4 g 聚山梨醇酐脂肪酸酯60 1.2 g 甲基酉旨(Methylparabene) 0.1 g 丙基 S旨(Propylparabene) 0.1 g 香料 0.1 g 純水 其他部分 總計 100 g 17 1308148 配方4.包含6-甲基-3-苯乙基-3,4-二氫-1丑-喳唑啉-2-硫酮化合 物之美白化妝品組合物-面膜 成分 含量 乙醇 6.0 g 甘油 4.0 g 聚乙烯基醇 15.0 g 玻尿酸萃取物 5.0 g 卢-葡萄聚糖 7.0 g 尿囊素 0.1 g 6-甲基-3-苯乙基-3,4-二氫 0.5g -1 σ坐琳-2-硫酉同 壬基苯基醚 0.4 g 聚山梨醇酐脂肪酸酯60 1.2 g 甲基酉旨(Methylparabene) 0.2 g 丙基醋(Propylparabene) 0.1 g 香料 0.1 g 純水 其他部分 總計 100 g 實驗實施例1:抑制黑色素經由cAMP/蛋白質酵素A產生之功效 在黑色素瘤B16細胞株中施與α -黑色素細胞刺激贺爾蒙, 使其藉由cAMP/蛋白質酵素Α訊號傳遞產生黑色素(Rasmussen, N., et al., Neuroendocrinol. Lett., 20:265-282, 1999; Scott, M. C., 心/·, 乂 Ce//H 115:2349-55, 2002)。黑色素瘤B16細胞懸浮於 18 1308148 添加10%牛胚胎血清之DMEM中谇 96孔平盤中,在37t、5% c〇 、JV,以2,5〇〇/孔之密度種於 將細胞分射㈣啦添加㈣°培養24小時後, 激賀爾蒙之實驗組、及同時#Λ 資)添加黑色素細胞刺 濃度岡和6-甲基·3·= 基^黑色素細胞刺激賀爾蒙(最後 劑之實驗組。每'组培養3天,心奎料1硫嗣為作用 決定被釋放至培養液中的黑色素含測波長奶⑽吸收值 實驗結果顯^制組之黑色素瘤m6 33.2土 l々g/ml之黑色素。沐Λ田“ 臀^天後釋放 、’、、σ α •黑色素細胞刺激賀爾蒙培養 之實驗組細胞釋放⑷见“心/如之”去门士貝爾冢^養 ..,.. 8 之…、色素。同h添加α -黑 色素細胞刺激贺爾蒙(最後濃度丨ηΜΗ〇 6_甲基_3_苯乙美_34二 氫-m-峻封_2_硫酮為作關之實驗組細胞,在仙^度,4 : Μ下釋放37.9± 0.8#g/ml之黑色素,在作用劑濃度2謂下釋 放44.4土 9.5/zg/ml之黑色素,在作用劑濃度下釋放ι〇ι ι ± 1.0# g /ml之黑色素,在作用劑濃度〇 5 # μ下釋放126.5± $ $ /z g /ml之黑色素。因此,細胞的表現顯示白化效果與劑量相關(第 la圖)。達到50%白化效果(EC%)時,有效劑量濃度為15wM。 在相同的實驗模型下,熊果苷及曲酸的白化效果ec50值分別顯示 為151//M及261//M。因此,我們注意到6-甲基-3-苯乙基-3,4- 二氫-1 套嗤°林-2-硫酮對黑色素瘤B16細胞株經由CAMP/蛋白質 酵素A訊號傳遞產生的黑色素脫色效果,就EC5()而言高於熊果 苷100倍且高於曲酸170倍(第lb圖)。 實驗實施例2:抑制黑色素經由cGMP/蛋白質酵素G產生之功 效 黑色素瘤B16細胞株以0比嗔紫質IX (ProtoP〇rphyrin IX )刺 激,經由cGMP/蛋白質酵素G利用一氧化氮產生黑色素 1308148 (Romero-Graillet, C., et aL, J. Biol. Chem., 271:28052-6, 1996)〇 m 色素瘤Bl6細胞懸浮於添加1〇%牛胚胎血清之dmem中培養了 以2,500/孔之密度種於96孔平盤中,在37。〇、5%c〇2的環境下 培養。培養24小時後,將細胞分成對照組(未添加任何化學物質)、 添加原1質IX之實驗組、及同時添加吡喀紫質Ιχ (最後濃度 #Μ)和6-曱基苯乙基_3,4_二氫_17/_喳唑啉_2_硫酮為作用^丨之 實驗組。每—組培養3天,然後藉由量測波長405mn吸收值決定 被釋放至培養液中的黑色素含量。 實驗結果顯示,對照組之黑色素瘤B16細胞培養3天後釋 放43.4± 0_8/zg/m丨之黑色素。添加吡喀紫質汊培養之實驗組細 胞釋放135.2± 1.9#g/ml之黑色素。同時添加吡喀紫質Ιχ(最後 濃度30//Μ)和6-甲基-3-苯乙基-3,4-二氫-i/f·喳唑琳_2_硫酮為作 用劑之實驗組細胞,在作用劑濃度! β M下釋放52 5± 5 8#呂 之黑色素,在作用劑濃度〇.5βΜ下釋放94 4± 6 〇"g /ml之黑 色素,在作用劑濃度〇.25//M下釋放1〇5·2土 〇 9#g /ml之黑色 素,在作用劑濃度〇.13/zM下釋放118·7± 32/zg/ml之黑色素。 因此,細胞的表現顯示白化效果與劑量相關(第以圖)。達到5〇% 白化效果(EC50)時,有效劑量濃度為0.5 #M。在相同的實驗模 型下’知果甘及曲酸的白化效果E(:5Q值分別顯示為159#M & 122 因此,實驗結果顯示6_甲基_3_苯乙基_3,4_二氫_ΐ7/_喳唑啉 -2·硫酮對黑色素瘤B16細胞株經由cGMp/蛋白質酵素G訊號傳 遞產生的黑色素脫色效果,就EC%而言高於熊果苷31〇倍且高於 曲酸240倍(第2b圖)。 實驗實施例3:抑制黑色素經由1-油醯-2-乙醯基甘油/蛋白質酵 素C產生之功效 黑色素瘤B16細胞株以1-油醯_2·乙醯基甘油刺激,經由蛋 20 1308148 白/酵素c產生黑色素(Gilchrest,B. A·,以从,戶^㈣
Photobiol, 93:1-10, 1996; Park, Η. Υ., ^ αί, J. Biol. Chem., 274:16470-8, 1999)。黑色素瘤Βΐ6細胞懸浮於添加1〇%牛胚胎血 清之DMEM中培養,以2,500/孔之密度種於96孔平盤中,在37 C、5% C〇2的環境下培養。培養24小時後,將細胞分成對照組(未 添加任何化學物質)、添加丨_油醯_2_乙醯基甘油之實驗組、及同 時添加1-油醯_2_乙醯基甘油(最後濃度2〇〇/zM)和6_甲基_3_苯乙 基-3,4-二氫_1/f_喳唑啉_2_硫酮為作用劑之實驗組。每一組培養3 天’然後藉由量測波長405nm吸收值決定被釋放至培養液中的黑 色素含量。 實驗結果顯示,對照組之黑色素瘤B16細胞培養3天後釋 放49.8± 1.0/mi之黑色素。添加卜油醯_2_乙醯基甘油培養之 實驗組細胞釋放1〇9_4± 0_2"§/〇11之黑色素。同時添加卜油醯-2· 乙醯基甘油(最後濃度20G//M)和6-f基冬苯乙基·3,4_二氫魯 喳唑啉-2-硫酮為作用劑之實驗組細胞,在作用劑濃度〇·5#μ下 釋放57.7± 2.9"g/ml之黑色素,在作用劑濃度〇.25_下釋放 82.2± 6.1#g/ml之黑色素,在作用劑濃度〇 下釋放1〇6 3 ± 〇.l#g /ml之黑色素,在作用劑濃度〇·〇6“Μ下釋放ι〇97土 〇々g/ml之黑色素。因此,細胞的表現顯示白化效果與劑量相 關(第3a圖)。達到50%白化效果(EC5〇)時,有效劑量濃度為〇3 在相同的實驗模型下’熊果芬的白化效果心值顯示為4乃 譯。因此’實驗結果顯示6-甲基_3_苯乙基_3,4_二氯_吸如圭啉 -2-硫㈣黑色素瘤B16細胞株經由蛋白質酵素c訊號傳遞產生 的黑色素脫色效果,就ec5〇而言高於熊果答157〇倍(第3b圖)。 實驗實施例4:白化機制減少路胺酸含量 黑色素瘤B16細胞懸浮於添加1〇%牛胚胎血清之讓咖中 21 1308148 培養’以2,500/孔之密度種於96孔平盤令,在37。(:、5% C02的 環境下培養24小時。在細胞中同時添加α _黑色素細胞刺激贺爾 蒙(最後濃度1 ηΜ)及6-甲基-3-苯乙基-3,4-二氫-1//-喳唑啉_2_巯 _為作用劑。在培養3天後,收集細胞、分散並離心。將懸浮物 當作酵素來源。20#g酵素來源以包含SDS之聚丙烯醯胺凝膠電 泳分離。然後,該凝膠以100mM之磷酸緩衝液(pH6 8)清洗以移 除SDS,再移至包含5 mM D〇pA之磷酸緩衝液(pH 6 8)中,並 避光保存於37°C。使用密度測定儀量測染黑之酪胺酸酵素含量。 與培養在含10%牛胚胎血清之DMEM培養液3天的黑色素瘤Bi6 細胞株產生的酪胺酸酵素相較,培養在相同培養液但添加α _黑色 素細胞刺激贺爾蒙中的黑色素瘤Β16細胞株產生的酪胺酸酵素增 加了 6至7倍。由只受到α _黑色素細胞刺激贺爾蒙刺激之黑色素 瘤Β16細胞株產生的酪胺酸酵素含量標示為1〇〇% ;由同時受到 黑色素細胞刺激賀爾蒙及6_甲基_3_苯乙基_3,‘二氫奎唑 琳-2-硫酮為作用劑刺激之黑色素瘤B16細胞株產生的絡胺酸酵 素3里,當作用劑濃度為4 " Μ時,酪胺酸酵素含量為丨7% ;作 用劑濃度為2譯時,絡胺酸酵素含量為35% ;作用劑濃度為i _時,赂胺酸酵素含量為83% ;作用劑濃度為〇 5_時,酪 胺酸酵素含里為92%,此-結果顯示抑制效果與劑量相關(第4 圖)。因此,本發明注意到6-甲基苯乙基_3,4_二氯套唆琳_2_ 硫酮藉由減少酪胺酸酵素含量的機制來達到脫色之效果。 實驗實施例S:對黑色素瘤Bl6細胞株之細跑毒性 黑色素瘤祕細胞懸浮於添加1〇%牛胚胎金清之丽舰中 料,以2,500/孔之密度種於96孔平盤中,在沉、5%叫的 衣i兄下養24小b。在細胞中同時添加黑色素細胞刺激贺爾 蒙(最後濃度1 _及6rn苯乙基m+M-2-硫 22 1308148 酮為作用劑。每24小時,存活與死亡的細胞素以錐蟲 blue)染色方法計算。與培養在含1()%牛胚胎血清之讓现培養 液的黑色素瘤Β16細胞株相較,培養在相同培養液但添加二里 色素細胞刺激贺爾蒙中的細胞顯示成長遲緩的現象,但並未表現 出殺死細胞的毒性(第5a圖)。在第四天,培養於添加心里色素 細曲胞刺激贺_蒙及6_甲基·3_苯乙基_3,4_h_b奎哇琳_2-伽 (濃度0.5至4#M)的細胞顯示出與培養在只添加^•黑色素細胞 刺激贺爾蒙細胞相同的存活細胞數,且未顯示出殺死細胞的毒性 (第5b圖)。 產業應用性 本發明提供一新穎具有優越美白功效之6_曱基_3_笨乙基 -3,4-二氫-1//-喳唑啉_2_硫酮化合物,能用於預防皮膚之黑色素過 度沉著症或淡化已累積於皮膚中的黑色素顏色,改善色素過度沉 著症如脫色及雀斑;該化合物之製備方法;及包含該化合物之醫 藥組合物及化妝品組合物。
23 l3〇8l48 【圖式簡單說明】 第la圖係為實驗實施例1之結果,顯示6_甲基笨乙美3 奎嗤琳_2_硫_經由cAMp/蛋白質酵素A 成之功效。 刺…、已素生 ,^係為實驗實施例丨之結果,係比較熊果*、曲酸與 土 _3_本乙基·3,4_二氫ϋ °坐琳-2-硫酉同經由cAMp ,素人抑制黑色素生成之功效。(·:本發明之化合物 ^ 甘曲酸) .見、果 第2a圖係為實驗實施例2之結果,顯示6_甲基」·苯乙美3斗 ,财唑啉_2_硫_經由_蛋白質酵“抑制 成之功效。 …、οι王
6_甲ί Γ?係為實驗實施例2之結果,係比較熊果#、曲酸與 土 --本乙基-3,4-二氫·1/7_口套嗤琳_2_硫調經由cGM
:素黑色素生成之功效。⑽:本發明之化合物〇: J
第3a圖係為實驗實施例3之結果,顯示6_甲基+苯乙& W ^㈣唾啉。姻經由卜油酿_2_乙醯基甘油:白質 酵素C抑似色素生成之功效。 ^ f 3b—圖係為實驗實_ 3之絲,係比較熊^、曲酸與 -土-3-本乙基-3,4-二氫_1私邊嗤琳_2_硫酮經&1_油醯_2_乙醯 基甘油(〇AG)/蛋白質酵素〇抑制黑色素生成 之化合物Ο:'熊果苷.▲:曲酸) (•本七月 第4圖係為實驗實施例4之結果,顯示由同時_ =刺激㈣蒙及6_甲基·3·苯乙基_3m奎棒 為作用劑刺激並培養於含10%牛胚胎血清之DMEM之黑色素瘤 B16細胞株產生之路胺酸酵素含量,相對於設為⑽之由只受到 黑色素細胞刺激贺爾蒙刺激之黑色素瘤B16細胞株產生之酪 24 1308148 月女醆酵素含量結果。 株择入圖係為實驗實施例5之結果,顯示黑色素瘤㈣細胞 養於相同培養液並添力-黑色素細:刺 H 之細胞增生成長結果H 〇··只添加α 株培:===果,顯示黑色素™ dm賺中、及培接相同培# 素細胞刺«爾蒙之 賀爾蒙和6•甲基_3_苯乙基_34二^寺添加α •黑色素細胞刺激 -.M)t 〇·3 25
Claims (1)
- 拾 、申靖專利範圍: —種6-甲其 ^ 卜 結構式(”土 Ί、-笨乙基_3,4_二氫_1/^奎唑啉_2_硫酮化合物,係如 h3c(1)0 種6-甲基-3-苯乙基-3,4-二氫-1//_喹唑啉_2_硫酮化合物之製 備方法,包含將結構式(4)所示之6-甲基-3-苯乙基-3,4-二氫_ι好_ °套嗤琳-2-酮與Lawesson's試劑反應。⑷ 如申請專利範圍第2項所述之方法,其中6_曱基_3_笨乙基_3,4_ 二氫-1//-喹唑啉·2_酮之製備方法,包含將結構式(2)所示之(5· 甲基-2-硝基苯)苯乙基胺還原,獲得結構式(3)所示之4甲基 -2-(苯乙基氨甲基)笨基胺,然後將產物4甲基_2_(笨乙基氨甲 基)苯基胺與1,Γ-羰基二咪唑反應,即製備得6-甲基_3_苯乙基 -3,4-二氮-奎。坐琳-2·嗣。26 (2)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020030057135A KR100747042B1 (ko) | 2003-08-19 | 2003-08-19 | 신물질6-메틸-3-펜에틸-3,4-디히드로-1h-큐나졸린-2-티온,이의 제조방법 및 이를 유효성분으로 포함하는 미백 효능조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200508208A TW200508208A (en) | 2005-03-01 |
| TWI308148B true TWI308148B (en) | 2009-04-01 |
Family
ID=34192126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092133158A TWI308148B (en) | 2003-08-19 | 2003-11-26 | Novel compound of 6-methyl-3-phenethyl-3,4-dihydro-1h-quinazoline-2-thione, its preparation and a depigmentation composition containing the same as an effective component |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR100747042B1 (zh) |
| AU (1) | AU2003282429A1 (zh) |
| TW (1) | TWI308148B (zh) |
| WO (1) | WO2005016895A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101104307B1 (ko) * | 2009-07-10 | 2012-01-11 | 충북대학교 산학협력단 | 신규 다이하이드로 퀴나졸린-2-싸이온 유도체 및 이를 함유한 미백용 조성물 |
| US8476251B2 (en) | 2010-07-29 | 2013-07-02 | Conopco, Inc. | Skin care compositions comprising substituted diamines |
| US8293218B2 (en) * | 2010-07-29 | 2012-10-23 | Conopco, Inc. | Skin care compositions comprising substituted monoamines |
| US20130273183A1 (en) * | 2012-04-13 | 2013-10-17 | Eastman Chemical Company | 2-Pyrimidine Thioesters and Thiocarbonates as Skin Brightening Agents |
| WO2017034214A1 (ko) * | 2015-08-24 | 2017-03-02 | 주식회사 아모라이프사이언스 | 미용 팩 및 그 제조방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3077046B2 (ja) * | 1992-08-31 | 2000-08-14 | 久光製薬株式会社 | 新規なキナゾリン誘導体 |
| US6750229B2 (en) * | 1998-07-06 | 2004-06-15 | Johnson & Johnson Consumer Companies, Inc. | Methods for treating skin pigmentation |
| JP4249855B2 (ja) * | 1999-08-31 | 2009-04-08 | 実 土屋 | 浮上ろ材を用いた移床式ろ過装置 |
| DE10008907A1 (de) * | 2000-02-25 | 2001-08-30 | Haarmann & Reimer Gmbh | Topische kosmetische Mittel enthaltend benzokondensierte oder heterocyclisch kondensierte 2-Hydrazino-1,3-heteroazole |
| GB0124627D0 (en) * | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
-
2003
- 2003-08-19 KR KR1020030057135A patent/KR100747042B1/ko not_active Expired - Fee Related
- 2003-11-25 AU AU2003282429A patent/AU2003282429A1/en not_active Abandoned
- 2003-11-25 WO PCT/KR2003/002545 patent/WO2005016895A1/en not_active Ceased
- 2003-11-26 TW TW092133158A patent/TWI308148B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050019401A (ko) | 2005-03-03 |
| TW200508208A (en) | 2005-03-01 |
| AU2003282429A1 (en) | 2005-03-07 |
| KR100747042B1 (ko) | 2007-08-07 |
| WO2005016895A1 (en) | 2005-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE1000320A3 (fr) | Nouveaux derives de piperazinyl-1 pyrimidine, leur preparation et leur application en therapeutique et en cosmetique. | |
| CN116672278A (zh) | 使用硫代吡啶酮化合物使角蛋白材料脱色的方法 | |
| CN101631532A (zh) | 抑制黑素原生成的化合物的组合及其在化妆品中和在皮肤病学中的应用 | |
| CN1507852A (zh) | 抗坏血酸衍生物作为漂白剂的美容用途 | |
| TWI308148B (en) | Novel compound of 6-methyl-3-phenethyl-3,4-dihydro-1h-quinazoline-2-thione, its preparation and a depigmentation composition containing the same as an effective component | |
| US20070258921A1 (en) | Process for depigmenting the skin | |
| KR20110097576A (ko) | 벤즈알데하이드 티오세미카바존 유도체를 함유한 미백용 조성물 | |
| KR20230073422A (ko) | 타이로시나제 저해 활성을 갖는 화합물을 포함하는 피부 미백용 조성물 | |
| WO2018053706A1 (en) | Composition comprising paeoniflorin or albiflorin analogue, method of preparation thereof | |
| KR100963441B1 (ko) | 신물질 1,3-디하이드로벤즈이미다졸-2-싸이온 유도체, 그의제법 및 이를 유효성분으로 하는 미백용 화장료 조성물 | |
| FR3067027B1 (fr) | Derives de resorcinol pour leur utilisation cosmetique | |
| JP4504520B2 (ja) | メラニン産生促進剤 | |
| KR102147604B1 (ko) | 소듐 서팩틴을 포함하는 탈모 방지 및 발모 촉진용 조성물 | |
| CA2261095C (fr) | Composes de la famille des 3-aryl 2,4 dioxo oxazolidines et leur utilisation en cosmetique et en pharmacie | |
| CN111132965B (zh) | 针对其美容用途的间苯二酚衍生物 | |
| KR100543954B1 (ko) | 1n-벤질-4-메틸벤젠-1,2-디아민, 그의 제조방법 및 그를함유하는 미백 화장품 조성물 | |
| KR102186533B1 (ko) | 불가리안 로즈오일 및 바위돌꽃뿌리 추출물을 포함하는 피부 미백용 화장료 조성물 | |
| KR20200103924A (ko) | 4-(4-메틸피페라진-1-일)-N-(5-(피리딘-3-일)-1H-피라졸로[3,4-b]피리딘-3-일)벤즈아미드 유도체, 또는 이의 약학적으로 허용 가능한 염의 미백용 소재 용도 | |
| JP4223723B2 (ja) | メラニン産生不全症予防治療剤 | |
| KR102164589B1 (ko) | 피리도[2,3-d]피리미딘-7(8H)-온 유도체 및 이를 유효성분으로 함유하는 피부 미백용 조성물 및 멜라닌 색소 과다 침착 질환의 예방 또는 치료용 약학적 조성물 | |
| KR20110005339A (ko) | 신규 다이하이드로 퀴나졸린-2-싸이온 유도체 및 이를 함유한 미백용 조성물 | |
| KR20100068258A (ko) | 피부, 체모 또는 모발에서 색소 형성을 유도, 회복 또는 자극하기 위한 2,2'-사이클로리그난의 용도 | |
| KR102163775B1 (ko) | 7-벤질-4(4-페닐피페라진-1-일)-7H-피롤로[2,3-d]피리미딘 유도체 및 이를 유효성분으로 함유하는 피부 미백용 조성물 및 멜라닌 색소 과다 침착 질환의 예방 또는 치료용 약학적 조성물 | |
| JP2022164564A (ja) | 皮膚美白用組成物およびこれを利用した皮膚美白方法 | |
| JPH11246344A (ja) | 美白用皮膚外用剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |